echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The GlaxoSmithKline shingles vaccine Shingrix received a key US FDA approval!

    The GlaxoSmithKline shingles vaccine Shingrix received a key US FDA approval!

    • Last Update: 2021-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    The GlaxoSmithKline (GSK) shingles vaccine Shingrix was approved for marketing in October 2017, and it almost broke through the blockbuster sales (sales of US$999 million) in its first full year on the market


    On Monday, the US FDA approved Shingrix to expand the applicable population for the vaccination of immune-compromised adults aged 18 and over to prevent shingles


    This FDA approval has opened up a new group of people for Shingrix


    This latest approval is based on research findings investigating the safety and effectiveness of Shingrix in adult patients undergoing stem cell transplantation and adult patients undergoing treatment for hematological malignancies


    According to a press release issued by GSK, Shingrix is ​​the first shingles vaccine approved for use in people with weakened immune functions


    The FDA approval comes at a time when GSK is trying to get Shingrix back on track


    In the early days of the COVID-19 pandemic, the Centers for Disease Control and Prevention (CDC) recommended that another vaccine should not be vaccinated within 2 weeks after the COVID-19 vaccine


    Reference source: As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine's reach

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.